Clinical trials: Patients with Multiple Sclerosis
Multiple Sclerosis
Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis
The primary objective is to assess the activity of nerispirdine in improving the ability to walk, in patients with multiple sclerosis (MS).
- Trial name
- NCT00811902
- Testing
- Nerispirdine
- Where
- 7 sites in United States, Canada and 5 more
- Volunteers
- 405 people
- Sponsor
- Sanofi
Multiple Sclerosis
OCT and Early Cognitive Impairment in Multiple Sclerosis
The aim of this study is to investigate the relationship between cognitive impairment and retinal nerve fiber layer \& ganglion cell inner plexiform layer in MS.
- Trial name
- NCT04153773
- Testing
- OCT
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Mansoura University Hospital
Multiple Sclerosis
The Effects of Muscles Strength on Physical Performance in Patients With Multiple Sclerosis
Muscle weakness, which is one of the most common symptoms in patients with MS, limits the activities of daily life activities of patients by causing balance and gait disturbance.
- Trial name
- NCT03597451
- Where
- Turkey (Türkiye)
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Gazi University
Multiple Sclerosis
Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
This research study is being conducted in the U.S. and Europe to evaluate the safety and efficacy of daclizumab for the treatment of multiple sclerosis (MS).
- Trial name
- NCT00109161
- Testing
- Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
- Where
- 36 sites in United States, Canada
- Volunteers
- 270 people
- Sponsor
- PDL BioPharma, Inc.
Idiopathic Parkinson's Disease, Multiple Sclerosis
Online Cognitive Training in PD, MS and Depressed Patients Treated With Electroconvulsive Therapy
In Parkinson's disease, Multiple Sclerosis and depressed patients treated with electroconvulsive therapy, cognitive dysfunction is prevalent. However, treatment of these dysfunctions is in its infancy.
- Conditions
- Idiopathic Parkinson's Disease, Multiple Sclerosis, Elderly Post Electric Convulsive Therapy
- Trial name
- NCT02525367
- Testing
- Online cognitive training, Active control condition
- Where
- Netherlands
- Volunteers
- 28 people
- Sponsor
- Amsterdam UMC, location VUmc
Multiple Sclerosis, Autoimmune Diseases
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis
The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients with Multiple Sclerosis and clinical outcomes?
- Conditions
- Multiple Sclerosis, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Nervous System Diseases
- Trial name
- NCT01453764
- Testing
- Harvesting and Implantation of SVF
- Where
- United States
- Sponsor
- Ageless Regenerative Institute
Bladder Outlet Obstruction, Multiple Sclerosis
GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology
Male self catherterisng observational study.
- Conditions
- Bladder Outlet Obstruction, Multiple Sclerosis, Cauda Equina Syndrome, Enlarged Prostate With Lower Urinary Tract Symptoms
- Trial name
- NCT05470751
- Testing
- Intermittent self-catheterisation
- Where
- 16 sites in United States, France and 1 more
- Volunteers
- 72 people
- Sponsor
- ConvaTec Inc.
Multiple Sclerosis
Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)
This study will: Explore whether GA decreases inflammation more on the 3T optimized protocol when compared to the 1.5T standard protocol.
- Trial name
- NCT00937157
- Testing
- Copaxone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University at Buffalo
Multiple Sclerosis
Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis
The primary objective is to evaluate the feasibility of the Multiple Sclerosis Performance Test (MSPT) in a clinical care setting when used by participants with Multiple Sclerosis (MS).
- Trial name
- NCT03926637
- Testing
- Multiple Sclerosis Performance Test (MSPT)
- Where
- 33 sites in United States, Czechia and 4 more
- Volunteers
- 3,073 people
- Sponsor
- Biogen
Multiple Sclerosis
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e.
- Trial name
- NCT03599245
- Testing
- Ocrelizumab
- Where
- 161 sites in Argentina, Belgium and 24 more
- Volunteers
- 1,055 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Ocrevus Zunovo for MS: Mixed Methods
Ocrevus Zunovo implementation, feasibility, acceptability, patient satisfaction, treatment persistence, and impact on MS disease outcomes will be analyzed in this mixed methods study.
- Trial name
- NCT07710105
- Testing
- Clinical Questionnaires, Semi-Structured Interviews, Ocrevus Zunovo
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Northwestern University
Amyotrophic Lateral Sclerosis, Muscle Cramp
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
The primary objective of the study is to demonstrate the safety and potential efficacy of TJ-68 for improving muscle cramps in participants with ALS based on a two-site, randomized, placebo-controlled double-blind multi-period…
- Trial name
- NCT04998305
- Testing
- TJ-68
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Hiroshi Mitsumoto
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
The primary study objective is to test the superiority of Daclizumab High Yield Process (DAC HYP) compared to interferon β 1a (IFN β-1a) in preventing multiple sclerosis (MS) relapse in participants with relapsing remitting…
- Trial name
- (DECIDE) (NCT01064401)
- Testing
- BIIB019 (Daclizumab High Yield Process), Interferon beta-1a
- Where
- 228 sites in United States, Argentina and 26 more
- Volunteers
- 1,841 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis (ALS)
Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)
The overall goal of this research is to delay the respiratory decline of patients with Amyotrophic Lateral Sclerosis (ALS) thereby increasing their lifespan by conditioning the diaphragm with laparoscopically placed electrodes.
- Trial name
- NCT00420719
- Testing
- Intramuscular diaphragm electrodes
- Where
- 8 sites in United States, France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Synapse Biomedical
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
The purpose of this study is to determine the safety and tolerability of the intranodal administration of autologous monocyte-derived dendritic cells tolerised with Vitamin-D3 and pulsed with myelin peptides (tolDC-VitD3) in…
- Trial name
- TOLERVIT-MS (NCT02903537)
- Testing
- Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3), Interferon-beta
- Where
- 2 sites in Spain
- Volunteers
- 16 people
- Sponsor
- Fundació Institut Germans Trias i Pujol
Multiple Sclerosis, Autonomic Nervous System Dysfunction
Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS
This study is designed to primarily evaluate the impact of Gilenya (Fingolimod) on the autonomic nervous system in patients being treated for the first time with Gilenya (Fingolimod).
- Trial name
- ANSG (NCT02048072)
- Testing
- Gilenya
- Where
- Switzerland
- Volunteers
- 33 people
- Sponsor
- Jochen Vehoff
Multiple Sclerosis
US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector
In this study researchers want to learn more about the medication usage behavior among multiple sclerosis (MS) patients treated with BETASERON using the myBETAapp.
- Trial name
- NCT04356339
- Testing
- Interferon-beta-1b (BETASERON, BAY 86-5046)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Bayer
Multiple Sclerosis
A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment
This is a multi-center, multi-regional observational,24 month study. Health-related quality of life data from the MusiQoL instrument and SF-36 instrument will be collected at baseline, M6, M12, M18 and M24 in patients with MS.
- Trial name
- MusiQoL (NCT00702065)
- Where
- 30 sites in United States, Argentina and 10 more
- Volunteers
- 599 people
- Sponsor
- EMD Serono
ALS, Amyotrophic Lateral Sclerosis
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis
Fosigotifator is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-part study.
- Trial name
- NCT04948645
- Testing
- Fosigotifator
- Where
- 14 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- AbbVie
Multiple Sclerosis
Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis
This was a retrospective cohort study utilizing the IQVIA PharMetrics® Plus claims database from 01 August 2019 through 31 May 2022.
- Trial name
- NCT06644638
- Where
- United States
- Volunteers
- 3,632 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.